Corporate Corruption News Stories

Excerpts of Key Corporate Corruption News Stories in Major Media

Below are key excerpts of revealing news articles on corporate corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

Note: This comprehensive list of news stories is usually updated once a week. Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

A safeguard for Medicare beneficiaries has become a way for drugmakers to get paid billions of dollars for pricey medications at taxpayer expense. The cost of Medicare’s “catastrophic” prescription coverage jumped by 85 percent in three years, from $27.7 billion in 2013 to $51.3 billion in 2015. Out of some 2,750 drugs covered by Medicare’s Part D benefit, two pills for hepatitis C infection - Harvoni and Sovaldi - accounted for nearly $7.5 billion in catastrophic drug costs in 2015. Medicare’s catastrophic coverage was originally designed to protect seniors with multiple chronic conditions from the cumulatively high costs of taking many different pills. Beneficiaries pay 5 percent after they have spent $4,850 of their own money. With some drugs now costing more than $1,000 per pill, that threshold can be crossed quickly. Lawmakers who created Part D in 2003 also hoped added protection would entice insurers to participate in the program. Medicare pays 80 percent of the cost of drugs above a catastrophic threshold that combines spending by the beneficiary and the insurer. That means taxpayers, not insurers, bear the exposure for the most expensive patients. Catastrophic spending accounts for a fast-growing share of Medicare’s drug costs, which totaled nearly $137 billion in 2015. The catastrophic share was 37 percent, yet only about 9 percent of beneficiaries reached the threshold for such costs. Catastrophic coverage will soon cost as much as the entire prescription program did when it launched. Experts say the rapid rise in spending for pricey drugs threatens to make the popular prescription benefit financially unsustainable.

Note: Read an excellent essay by former New England Journal of Medicine editor Dr. Marcia Angell exposing The Truth About the Drug Companies. For more along these lines, see concise summaries of deeply revealing Big Pharma profiteering news articles from reliable major media sources.

The images that shaped public imagination of the American Indian - 19th and early 20th century photographs - were mostly fiction. Often, they were sentimentalized portrayals of what Edward S. Curtis, the most successful of all who trained their cameras on the subject, called “the vanishing race.” The ... pictures glossed over attitudes and policies that today are seen as cruelly neglectful, if not genocidal. Curtis himself, funded with J.P. Morgan money to produce some 40,000 photographic documents for his magnificent 20-volume “The North American Indian,” is known to have choreographed ceremonies and dances, phonied up costumes, retouched negatives to remove all signs of modernity; he paid reservation residents to play the part of native nobility. Other photographers purported to show the fearsomeness of the American Indian warrior. Two ... intensely engaging exhibitions newly opened at the California Historical Society present images of Northern California and southern Oregon’s Modoc tribe. “Sensationalist Portrayals of the Modoc War, 1872-73” examines reports of a sad chapter of American history, when a band of about 60 Indian fighters held off 600 U.S. Army troops. “Native Portraits: Contemporary Tintypes by Ed Drew” features Drew’s revival of a 19th century photographic process to depict present-day Modocs as they choose to be seen. Side by side, the two shows add up to a quiet rebuke of photography’s cravenly racist portrayal of the first Americans.

Note: For more along these lines, see concise summaries of deeply revealing media corruption news articles.

Naloxone works by blocking the effect that painkillers and heroin have in the brain and reversing the slowed breathing and unconsciousness that come with an overdose. But as the demand for naloxone has risen - overdose deaths now total 130 every day, or roughly the capacity of a Boeing 737 - the drug’s price has soared. Not long ago, a dose of the decades-old generic drug cost little more than a dollar. Now the lowest available price is nearly 20 times that. In 2014, more than 47,000 Americans died from drug overdoses. That was 50% more deaths than from highway accidents ... and more overdose deaths than any year on record. The overdose crisis has its roots in the 1990s, when doctors began prescribing more and higher doses of painkillers [in response] to campaigns, often funded behind the scenes by drug makers, that urged doctors to prescribe the strongest painkillers not just to cancer patients and others in severe pain, but also to those with milder pain. The narcotic manufacturers’ funding of those campaigns ... came to light through evidence unearthed in lawsuits and investigative journalism reports. Since 1999, the amount of prescription opioids such as oxycodone, morphine and hydrocodone sold in the U.S. nearly quadrupled. During that same time, deaths from those drugs quadrupled. The lethal side effects of that booming prescription painkiller market has now sparked a moneymaking opportunity with naloxone.

Note: Tens of thousands of deaths are caused by prescription opioid overdose in the US each year. If Big Pharma sees this as an opportunity to profit, what does that say about the healthcare system?

In August 2015, Turing Pharmaceuticals and its then-chief executive, Martin Shkreli, purchased a drug called Daraprim and immediately raised its price more than 5,000 percent. Within days, Turing contacted ... PSI, a charity that helps people meet the insurance copayments on costly drugs. Turing wanted PSI to create a fund for patients with toxoplasmosis, a parasitic infection that is most often treated with Daraprim. Having just made Daraprim much more costly, Turing was now offering to make it more affordable. But this is not a feel-good story. It’s a story about why expensive drugs keep getting more expensive, and how U.S. taxpayers support a billion-dollar system in which charitable giving is, in effect, a very profitable form of investing for drug companies - one that may also be tax-deductible. PSI, which runs similar programs for more than 20 diseases, jumped at Turing’s offer. PSI is a patient-assistance charitable organization, commonly known as a copay charity. It’s one of seven large charities ... offering assistance to some of the 40 million Americans covered through the government-funded Medicare drug program. A million-dollar contribution from a pharmaceutical company to a copay charity can keep hundreds of patients from abandoning a newly pricey drug. Fueled almost entirely by drugmakers’ contributions, the seven biggest copay charities, which cover scores of diseases, had combined contributions of $1.1 billion in 2014. For that $1 billion in aid, drug companies “get many billions back” from insurers.

Note: For more along these lines, see concise summaries of deeply revealing pharmaceutical industry corruption news articles from reliable major media sources.

It's the time of year when experts crunch the numbers to see how well the flu shot worked. The result? Better than last year, but still not good enough. "Just shy of 45 to 50 per cent," said Dr. Danuta Skowronski of the BC Centre for Disease Control, who presented the data to the Global Influenza Vaccine Effectiveness meeting at the World Health Organization last week. In 2014-15, the flu shot offered essentially zero protection against the circulating influenza virus of that season. Back then, the prevailing strain was H3N2. This year's main circulating virus was H1N1. Skowronski said the vaccine was ... disappointing. Experts used to believe the annual flu shot protection was much higher, around 70 to 90 per cent. But not anymore. Those early estimates were based on industry-funded clinical trials that were extrapolated to apply across all ages and flu seasons. "It was a blanket assumption that is simply not true," Skowronski said. That assumption changed dramatically, after Skowronski and colleagues developed a protocol that revealed the true picture of vaccine efficacy. It's called the test negative design (TND) first piloted in Canada in 2004. "The test negative design has opened our eyes to all kinds of variables that we were blind to for years," said Skowronski. Scientists also once again observed [that] people who get the shot with no prior vaccine exposure seem to have better protection than people who get the shot year after year.

Note: A National Institute of Health study found in 2007 that flu shots do not protect the elderly. More recent studies have shown that some flu shots actually increase the risk of infection. For more along these lines, see concise summaries of deeply revealing vaccine controversy news articles from reliable major media sources.

Eric Holder has long insisted that he tried really hard when he was attorney general to make criminal cases against big banks in the wake of the 2007 financial crisis. [Yet Holder] held his department back [according to] a new, thoroughly-documented report from the House Financial Services Committee. Prosecutors in 2012 wanted to criminally charge the global bank HSBC for facilitating money laundering for Mexican drug lords and terrorist groups. But Holder said no. In September 2012, the Justice Department’s Asset Forfeiture and Money Laundering Section (AFMLS) formally recommended that HSBC be prosecuted for its numerous financial crimes. From 2006 to 2010, HSBC failed to monitor billions of dollars of U.S. dollar purchases with drug trafficking proceeds in Mexico. It also conducted business going back to the mid-1990s on behalf of customers in Cuba, Iran, Libya, Sudan, and Burma, while they were under sanctions. Such transactions were banned by U.S. law. AFMLS Chief Jennifer Shasky wanted to seek a guilty plea for violations of the Bank Secrecy Act. On November 7, Holder presented HSBC with a “take it or leave it” offer of a deferred prosecution agreement, which would involve a cash settlement and future monitoring of HSBC. No guilty plea was required. HSBC [then] successfully negotiated to have individual executives immunized from prosecution. Lack of desire at the highest levels of the Justice Department was ... the primary reason that no prosecutions took place.

Note: While attorney general of the United States, Eric Holder consistently refused to prosecute Wall Street. For more along these lines, see concise summaries of deeply revealing news articles about corruption in government and in the financial industry.

In 2014, a man testified that Penn State football coach Joe Paterno ignored his complaints of a sexual assault committed by assistant coach Jerry Sandusky in 1976 when the man was a 14-year-old boy, according to court documents unsealed Tuesday. Four other former assistant football coaches at the school also were aware of Sandusky acting inappropriately with boys before law enforcement was first notified in 1998, according to testimony contained in the documents. The allegations suggest that Paterno may have been made aware of Sandusky’s actions far earlier than has previously been reported, and that knowledge of Sandusky’s behavior may have been far more widespread among the Penn State football staff than previously known. The trove of documents unsealed Tuesday came from a legal dispute between the university and an insurance company over the responsibility for nearly $93 million the school paid in settlements with victims. Additionally, the Paterno family is suing the NCAA for defamation and commercial disparagement; the NCAA is considering using some of the information released Tuesday in its defense. In the Penn State community, an alumni group is pushing for a bronze statue of Paterno to be restored on campus, and for the university to repudiate a 2012 report by former FBI director Louis Freeh that blamed Paterno, other university leaders and a “culture of reverence for the football program” for Sandusky’s rampant sexual abuse.

Note: Read more about how senior Penn State officials covered up Sandusky's crimes due to fears of bad publicity. Watch an excellent segment by Australia's "60-Minutes" team "Spies, Lords and Predators" on a pedophile ring in the UK which leads directly to the highest levels of government. A second suppressed documentary, "Conspiracy of Silence," goes even deeper into this topic in the US. For more along these lines, see concise summaries of deeply revealing sexual abuse scandal news articles from reliable major media sources.

Nearly all food labels in Vermont are now required to disclose when products include genetically engineered ingredients. The requirement, passed two years ago, became effective on Friday. The rule is the first of its kind in the United States, and although it applies only within the tiny state, it is having national impact. Most major food and beverage companies have already added language to their labels to meet the new rule, rather than deal with the logistical hassle of having separate labels for different states. But not all the same products will definitely be on shelves. Vermont’s law requires the labeling of most packaged grocery products as well as any whole fruits or vegetables produced with genetic engineering. That means virtually all products containing derivatives of crops like corn, soy, canola and sugar from sugar beets will need labels, as most of those crops in the United States are grown from genetically modified seeds. Vermont’s law is careful, however, to exclude cheese, a big business in the state. The law also exempts meat from animals that have eaten feed made from genetically engineered grains. The labeling issue has generated heavy and frantic lobbying by the Grocery Manufacturers Association and the trade groups representing major commodity producers of crops like soy and corn, who have wanted a federal law that would prevent mandatory labels.

Note: On July 8, the US Senate passed a bill which allows food companies to continue to avoid clear GMO ingredient labeling. Let's hope it does not pass the full Congress and become a law. For more along these lines, see concise summaries of deeply revealing food industry corruption and GMO news articles from reliable major media sources.

On September 18, 2015, Guatemalan professor Rigoberto Lima Choc awaited a judge’s decision on an issue he had been the first to uncover: A company was polluting the waters of La Pasión River. Lima Choc had not only documented and reported the problem but had also taken journalists and photographers to witness the fish slaughter. That day, as he walked down the steps of the courthouse, two men on a motorcycle approached and fired at him. He died on the spot. Lima Choc’s death is, sadly ... not an exception. Through 2015 a worldwide total of 185 murders of this kind were documented by the nongovernmental organization Global Witness. A detailed report on these deaths ... implies a significant growth from one year to the next. Latin America had the dubious honor of being the region with the highest number of conservationist murders - 122; Brazil took the lion’s share with 50 killings. Indigenous communities are especially vulnerable, and it is there where most environmental activists are killed. Just a few cases [leave] a documented record. Osvaldo Durán, spokesman of the Costa Rica–based Federation for the Conservation of the Environment ... points out that many times the government does nothing to defend people or groups under attack; and that sometimes it even orchestrates disinformation campaigns. Duran says, “The economic model ... requires a fusion of interests between [the] state and corporations. This is when you see the state defending private interests instead of communities.”

Note: For more along these lines, see concise summaries of deeply revealing news articles about corruption in government and in the corporate world.

Physician influence can be bought for as little as a $20 meal, UCSF researchers have found. A study published Monday in JAMA Internal Medicine ... found that doctors who received just one meal averaging $20 were up to twice as likely to prescribe brand-name drugs being promoted than doctors who did not receive any free food. Gifts from pharmaceutical companies to doctors ... have come under scrutiny in recent years for concerns that the money spent by drugmakers directly influences what physicians write on their prescriptions pads. Some doctors deny they’re influenced by money, but a growing number of studies show that financial ties can affect their professional behavior. The UCSF researchers looked at ... the routine briefings many doctors and their staff receive from drug reps during lunches in their offices. The study found that the effect increased as doctors got more meals. Those who received multiple meals were up to three times as likely to prescribe the promoted brand-name drug. Higher-cost meals were associated with greater influence. Doctors who received four or more meals to promote Allergan’s Bystolic to treat hypertension prescribed the drug at 5.4 times the rate of physicians who received no meals. For Pfizer’s depression drug Pristiq, that rate was 3.4 times higher. UCSF researchers said that their studies show the buying power of drug makers decreases the use of cheaper, generic drugs and raises costs for patients as well as the health care system.

Note: For more along these lines, see concise summaries of deeply revealing big Pharma profiteering news articles from reliable major media sources.

The security firm that employed Orlando shooter Omar Mateen concluded that allegations about his inflammatory comments while an armed guard in 2013 were serious enough to transfer him to an unarmed position. But the company, G4S Secure Solutions USA Inc., dropped the matter [and] did not take away his company-issued service weapon. That decision, coupled with the fact that Mateen underwent three separate inquiries by the FBI in 2013 and 2014, raises questions about whether G4S - the U.S. subsidiary of one of the world's largest security firms - properly vetted Mateen in the years before Sunday's mass shooting at the Pulse nightclub. Former G4S security guard Daniel Gilroy ... complained repeatedly about Mateen to supervisors at G4S. They ignored his concerns. Ultimately, Gilroy said, he quit rather than have to face Mateen, who he said threatened him. [A company official] said G4S has so far found no evidence of any other employees making complaints about Mateen, including those who worked at the St. Lucie County Courthouse with him in 2013. FBI Director James Comey said earlier this week that colleagues said Mateen claimed to have family connections to terror groups al Qaeda and Hezbollah, and that he hoped law enforcement would raid his home "so he could martyr himself." Those remarks prompted courthouse officials to request Mateen's immediate removal from the St. Lucie County Courthouse, and to make "the appropriate notifications to inform our federal partners," including the FBI.

Note: For more along these lines, see concise summaries of deeply revealing news articles about corporate corruption and terrorism.

Nine years ago, the state of Florida received documentation from a security firm vouching for the mental health of Omar Mateen, who launched a bloody attack this week on Orlando nightclub patrons. But the psychologist whose name appears on the document in state records said Friday that she never evaluated [Mateen]. In fact, she wasn’t even living in Florida when the evaluation was supposedly completed. The revelation Friday became another source of scrutiny for the G4S security firm, which was known as Wackenhut at the time. The psychological evaluation done for the company, which is required under state law, cleared Mateen to carry a firearm as a private security guard. “What I do know is that in September 2007, I was not living or working in Florida, I was not performing any work for Wackenhut, and I did not administer any type of examination to Omar Mateen,” Dr. Carol Nudelman, who now lives in Colorado, said in a statement. The global security firm - which does work in more than 100 countries - is locally based in Jupiter. Its operations have come under scrutiny a number of times over the years. In the mid-2000s, G4S was accused of overbilling Miami-Dade County taxpayers of at least $3 million for security services that were not actually provided. But a criminal case against company employees fizzled in 2012.

Note: A CBS News story titled, "Locked Inside a Nightmare" sheds light on Wackenhut's profoundly corrupt history. For more along these lines, see concise summaries of deeply revealing corporate corruption news articles from reliable major media sources.

The fast rise of Sen. Elizabeth Warren within the Democratic Party has coincided with another phenomenon: the continual use by elite-media journalists of anonymous sources in articles that either criticize Warren directly or warn other politicians about the dangers of embracing ... the policies she advocates. That journalistic trend manifested itself most recently on Monday, in a piece by Ben White in Politico that quoted fully five anonymous sources - including “one top Democratic donor,” “one moderate Washington Democrat” and “one prominent hedge fund manager” - to the effect that Hillary Clinton would be making a major misstep by selecting Warren as her running mate. Warren is an expert in bankruptcy and predatory lending and a leading critic of the financial industry. Is the “top Democratic donor” Politico quoted a self-interested executive at Citigroup or Goldman Sachs fearful that Warren would influence policy decisions? We’ll never know. Journalists in this way let powerful individuals take potshots without any fear of accountability and without the reader being able to discern what conflicts of interest might be involved. And when it comes to Warren in particular, pretty much any “administration official” or “political strategist” interested in advancing a narrative gets the anonymous treatment. The Intercept in short order compiled a list of 15 other articles and political newsletters over the last few years of the anonymously sourced, anti-Warren genre.

Note: The complete list of examples of anti-Warren propaganda articles is available at the link above. For more along these lines, see concise summaries of deeply revealing media manipulation news articles.

Genentech and another drugmaker will pay $67 million to settle claims that they misled doctors into prescribing a treatment to lung cancer patients for whom the companies knew it would not work. As a result, some patients may have died earlier than they would have if they had taken more effective drugs, a lawsuit brought by a former Genentech employee and joined by federal prosecutors alleges. From 2006 to 2011 Genentech and its marketing partner OSI Pharmaceuticals promoted Tarceva to treat all patients with non-small-cell lung cancer even though studies had shown that it worked for just those who had never smoked or had a certain gene mutation known as EGFR. Epidermal growth factor receptor is a type of protein found on the surface of cells in the body. The whistle-blower lawsuit was filed in 2011 by Brian Shields, who worked as a Tarceva sales representative and then a product manager. The lawsuit said the companies ... discouraged doctors from testing patients for EGFR. The companies also promoted Tarceva ... by giving doctors illegal kickbacks disguised as fees for making speeches or serving on Genentech’s advisory boards. Sales representatives across the country were “instructed to spend lavishly” on physicians, the case said, and given “an unlimited budget to wine and dine.” Genentech also organized lunches or dinners for lung cancer patients where “patient ambassadors” were paid fees to speak about how Tarceva could be used in ways never approved by regulators, the lawsuit said.

Note: While Genentech was inaccurately describing its new drugs to doctors and patients, this company was also fiercely lobbying to prevent others from selling affordable alternatives to its costly drugs. Practices like this, along with the suppression of promising cancer research, show how Big Pharma puts profit before people.

If you want an example of how bizarre U.S. tax laws can be - and how companies can game the system - look no further than the recently announced deal for Johnson Controls Inc. of Milwaukee to desert our country by combining with a previous corporate deserter, Tyco International PLC. Tyco is run out of Princeton, N.J., but for tax purposes it is based in Ireland, where the combined Johnson Controls PLC will be based. This [is] an especially aggressive transaction that, among other things, will let Johnson game the tax system by handing its shareholders about $3.9 billion in cash in order to get tax-free access to $8.1 billion in cash currently held overseas. Under our tax laws, if a U.S. company combines with a foreign company (or a nominally foreign company such as Tyco), it can play a variety of tax games, provided that the shareholders of the U.S. company own more than 60 percent but less than 80 percent of the stock in the new, combined company. However, the company can play far more games ... if the shareholders of the U.S. company own more than 50 percent of the combined company but less than 60 percent. By being in [this] sweet spot, Johnson PLC can get its hands on its offshore cash directly, instead of having to leap through various hoops. [Who knows] why it’s legal for Johnson to buy in a chunk of its shares to make the numbers work - but apparently, it is. So there you have it. Johnson, a vendor to the taxpayer-rescued U.S. auto industry, repays us by doing ... a mega-desertion.

Note: Under current US laws, in what the Washington Post calls a "corporate predator state", profitable multinationals often pay no US taxes at all. For more along these lines, see concise summaries of deeply revealing corporate corruption news articles from reliable major media sources.

In April, the email in-boxes of energy executives filled with alerts from the nation’s top corporate law firms. The subject: the multistate investigation into whether Exxon Mobil committed fraud by publicly discounting the impact of fossil fuels on climate change. The investigations into whether their industry suppressed findings and misled investors, policymakers and the public about global warming not only raise the prospects of criminal charges, but add momentum to a legal campaign [comparable] to the decades-long battle against Big Tobacco. In April, a federal judge in Oregon ruled that a case against the U.S. government for inaction on climate change could proceed, explaining that “the alleged valuing of short term economic interest despite the cost to human life” required examination by the courts. Environmental lawyers have argued for years that governments and companies are legally obligated to reduce greenhouse gas emissions. They had little success, with the U.S. Supreme Court ruling in 2011 that the federal government alone had the power to control carbon emissions. But the recent entry of state prosecutors into the legal battle opens up a new line of inquiry: Did fossil fuel companies mislead their investors and the public on their own views on climate change and the risk it posed to their business? The recent legal rush follows the revelation last year that Exxon had engaged in climate change research in the 1970s and ’80s, and was warned by its own scientists of the growing threat.

Note: Read about the recent New York Attorney General's investigation into Exxon's climate change lies. For more along these lines, see concise summaries of deeply revealing climate change news articles from reliable major media sources.

Prime ministers, finance ministers, leading entrepreneurs and a former spy chief are among the attendees at this year’s influential Bilderberg conference ... which begins on Thursday in Dresden. The German military has been drafted in to oversee security. They’re working with corporate security from Airbus to make sure the politicians are kept safely away from the press for the entire three-day conference. Every year, a major corporation with links to the Bilderberg steering committee coordinates security for the event with the police. Which makes the whole conference even more obviously the corporate lobbying event that it is - with giant corporations handling everything from security to dry ice. And it makes the silence of the politicians who attend even more egregious. These high-level talks between policymakers and the heads of transnational oil companies ... take place in heavily guarded privacy, with no press oversight whatsoever. [This is] especially great if you’re on the board of BP. Like, for example, Sir John Sawers. As well as being a director of BP, the silken, Blairish former MI6 boss is a member of Bilderberg’s steering committee, and the chairman of Macro Advisory Partners, a global advisory group with heavy links to the transatlantic intelligence community, very much in the style of Kissinger Associates. And speak of the devil! The ageless 93-year-old former US secretary of state will be holding court at Dresden, croaking out his wisdom from the throne of bones he has shipped everywhere he goes.

Note: This entire article is a must read if you want to know how the power elite work together to manipulate global politics. For more along these lines, see concise summaries of deeply revealing news articles on the Bilderberg Group and other elite secret societies.

More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. Clinical trials ... seemed to support their optimism. Patients needed just a fraction of the dose, creating the chance of far fewer dangerous side effects. But in 2004 ... Gilead executives stopped the research. The results of the early patient studies would go unpublished for years as the original medication - tenofovir - became one of the world’s most-prescribed drugs for HIV, with $11 billion in annual sales. In 2010, Gilead restarted those trials. A year of treatment with Gilead’s HIV medicines costs about $30,000. Earlier this year, the Los Angeles-based AIDS Healthcare Foundation, which operates clinics and pharmacies for AIDS patients, sued Gilead, contending that it delayed the less toxic form of tenofovir to manipulate the patent system and keep prices artificially high. Animal studies showed that [tenofovir] could cause damage to the kidneys and bones. When the drug was approved in 2001, the FDA required Gilead to study whether the medicine would harm humans in the same way. [By] 2003, the company had received so many reports of patients experiencing kidney failure and other ... problems that it placed a warning on the drug’s label. Several times, U.S. regulators formally warned Gilead that it was downplaying the drug’s risks.

Note: After the FDA warned Gilead that its sales reps were illegally lying to doctors about tenofovir's safety, Gilead continued misrepresenting this drug, prompting the FDC to send the company a rare second warning letter. For more along these lines, see concise summaries of deeply revealing big Pharma profiteering news articles from reliable major media sources.

Environmentalists have taken to streets around the world to protest against seed giant Monsanto at the same time as the company is facing a $62 billion takeover by Bayer, the German drugs giant. More than 400 simultaneous demonstrations against genetically modified crops and pesticides were organised around the world this weekend. The protests took place in over 40 countries. They come come as Monsanto faces an unsolicited takeover offer by Bayer, the chemical giant that invented aspirin. The deal could create the world’s biggest supplier of farm chemical and genetically modified seeds. Up to 3,000 protesters, rallied by environmental organisations including Greenpeace and Stop TAFTA, an anti-capitalist group, gathered in Paris, according to Agence France Presse. Protesters voiced their anger against Monsanto’s herbicide Roundup which is classified as “probably carcinogenic to humans” by the World Health Organisation. In the US, where 90 per cent of corn, soybean and cotton is genetically modified, campaigners promoted the march with a billboard in Times Square, showing a topless model and the slogan: “Keep GMOs out of your genes.” On Monday Bayer made an unsolicited $62 billion all-cash offer to acquire Monsanto. A concentration of corporate power in the agriculture and chemical sector would be bad news for both farmers and consumers. It would accelerate the decrease in crop diversity while limiting consumer choice. Farmers would ... find it harder to choose what they grow and how they grow it.

Note: Bayer's pesticides have been implicated in the collapse of bee populations. Glyphosate, the main ingredient in Monsanto's "RoundUp" pesticide, is now the most heavily-used agricultural chemical ever and probably causes cancer. For more along these lines, see concise summaries of deeply revealing GMO news articles from reliable major media sources.

CEOs at the biggest companies got a 4.5 percent pay raise last year. That's almost double the typical American worker's, and a lot more than investors earned from owning their stocks - a big fat zero. The typical chief executive in the Standard & Poor's 500 index made $10.8 million, including bonuses, stock awards and other compensation, according to a study by executive data firm Equilar for The Associated Press. That's up from the median of $10.3 million the same group of CEOs made a year earlier. The raise alone for median CEO pay last year, $468,449, is more than 10 times what the typical U.S. worker makes in a year. The median full-time worker earned $809 weekly in 2015, up from $791 in 2014. "With inflation running at less than 2 percent, why?" asks Charles Elson, director of the John L. Weinberg Center for Corporate Governance at the University of Delaware. The answer is complicated. CEO pay packages now hinge on multiple layers of sometimes esoteric measurements of performance. That's a result of corporate boards attempting to respond to years of criticism ... from Main Street America, regulators and even candidates on the presidential trail this year. One bright spot, experts say, is the rise in the number of companies that tie CEO pay to how well their stocks perform. "There's progress generally in aligning compensation with shareholder returns," says Stu Dalheim, vice president of governance and advocacy at Calvert Investments. "But I don't think this compensation is sustainable."

Note: For more along these lines, see concise summaries of deeply revealing income inequality news articles from reliable major media sources.

Important Note: Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.